promethazine hydrochloride and dextromethorphan hydrobromide
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (promethazine hydrochloride and dextromethorphan hydrobromide) by ANI Pharmaceuticals is clinical pharmacology promethazine promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1957.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
Promethazine HCl and Dextromethorphan HBr is a fixed-dose combination oral syrup that combines an H1 receptor antagonist with antihistaminic and sedative properties (promethazine) and a non-narcotic antitussive agent (dextromethorphan). It is indicated for symptomatic relief of cough and upper respiratory symptoms associated with allergies and the common cold. The combination works through central nervous system mechanisms: promethazine blocks histamine receptors while providing sedation and antiemetic effects, while dextromethorphan elevates the cough reflex threshold.
This legacy product approaching loss of exclusivity represents a declining commercial opportunity with likely team consolidation and focus on generic transition management.
CLINICAL PHARMACOLOGY PROMETHAZINE Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…
Worked on PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moJoining the promethazine-dextromethorphan team offers minimal career growth opportunity as the product approaches loss of exclusivity with zero linked job openings and declining commercial resources. This is a consolidation-phase role suited for professionals managing portfolio wind-down, regulatory compliance, or transition to generic manufacturing rather than building commercial momentum.